# ILoveMyBody Psoriasis — End-to-End Handover

## Status

The psoriasis project is structurally complete as a governed research/clinical execution system.

- Encyclopedia: Phase 106
- Genetic -> modifiable pathway: Phase 107
- Governing equations / coefficient registry: Phase 108
- First-principles derivation + verification isolation: Phase 109
- IL-17 mass balance / binding / transport: Phase 110
- Keratinocyte population / geometry: Phase 111
- IL-17 intracellular signaling network: Phase 112
- G1/S cell-cycle bridge: Phase 113
- Differentiation / cornification / barrier / resolution: Phase 114
- Master formula closure: Phase 115
- Primitive numeric closure registry: Phase 116
- Episode-to-verification orchestration: Phase 117

## Master scientific conclusion

Psoriasis is genetically influenced but active psoriasis is not equivalent to genotype. The working chain is:

`fixed susceptibility -> immune set point -> IL-23/Th17/IL-17 -> IL-17 receptor -> ACT1/TRAF6 -> NF-kB/MAPK/YAP/EGFR -> G1/S cell cycle -> proliferative/differentiated/corneocyte population balance -> cornification/desquamation -> barrier -> epidermal thickness -> plaque excess`.

The physical plaque endpoint is:

`V_excess = A_lesion * max(h_epi - h_normal, 0)`

with:

`h_epi = (N_p*v_p + N_d*v_d + N_c*v_c)/A_lesion`.

Necessary regression conditions are:

1. `r_commit + r_apop,p > r_self`
2. `(r_corn + r_apop,d)*N_d > r_commit*N_p`
3. `r_shed*N_c > r_corn*N_d`
4. `dV_excess/dt < 0`
5. `h_epi -> h_normal` and barrier index `B -> 1`.

## Project rule

`DERIVE -> PREDICT -> VERIFY`.

No external modality workbook may create a biological coefficient or mechanism. Homeopathy, Bach, Louise Hay, Redikall, EMDR, acupuncture and other modality datasets may be used as independent verification/hypothesis layers unless a mechanism is independently derived and sourced.

## Episode execution flow

1. Create psoriasis episode.
2. Run urgent safety screen (GPP, erythrodermic psoriasis, infection signal, PsA signal).
3. Capture baseline state: phenotype, PASI/BSA, itch/DLQI, target plaque, calibrated lesion geometry, TEWL/OCT where available, photographs and relevant measured modifiers.
4. Read primitive closure state. Predictions are blocked where required primitives are missing.
5. Create a node-specific intervention plan with directness, evidence status, biological claim boundary and measurement endpoint for every plan item.
6. Generate only formula-supported predictions.
7. Record intervention exposure without implying mechanism.
8. Record follow-up checkpoint.
9. Compare prediction vs observation using residual/error.
10. Update evidence status only after independent verification.
11. Close episode only after outcome, safety and evidence records are complete.

## Evidence-convergent non-drug conclusion

- Controlled phototherapy is the strongest established direct non-drug psoriasis intervention/reference pathway.
- Barrier care directly supports downstream barrier/scaling/fissure state.
- Weight/metabolic correction is conditional where a measured abnormality exists.
- Sleep/exercise/stress interventions are upstream modifiers.
- EMDR is an upstream trauma/distress/autonomic modifier, not a direct IL-17 treatment.
- Acupuncture remains a candidate adjunct with incomplete quantitative mechanistic closure.
- Homeopathy/Bach/Louise Hay/Redikall remain verification/hypothesis/narrative layers unless an independent mechanism is established.

No universal alternate replacement for an IL-17 biologic and no universal alternate cure has been established.

## Remaining scientific work

The structural formula is complete. Numeric closure remains finite and explicit. Highest-priority unresolved primitives include matched IL-17 association/dissociation kinetics, effective tissue half-life/clearance, receptor abundance/availability per keratinocyte, signaling kinetic constants, commitment/cornification/shedding rates, barrier transport primitives, cell volumes and person-specific lesion geometry.

These values must come from physical/chemical laws, matched biological measurements, geometry or person-specific measurement. They must not be free regression coefficients.

## Deployment status

Repository architecture is complete through Phase 117. Production database / Google Cloud synchronization is a separate operational gate and must be verified with deployment proof. Do not infer production synchronization merely from GitHub merge status.
